Published: 16 February 2023
Author(s): Dimitrios Patoulias, Athina Dimosiari
Issue: April 2023

Corticosteroids still represent one of the cornerstone treatment options for subjects hospitalized with coronavirus disease 2019 (COVID-19), especially for those suffering from a severe form of the disease [1–3]. Pulse methylprednisolone administered intravenously is a widely accepted treatment strategy for the induction of recession in subjects with acute flare or exacerbation of a background autoimmune disease, such as systemic lupus erythematosus, systemic vasculitis, or multiple sclerosis [4].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.